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ABSTRACT
Objective. Primary cardiac manifesta-
tion is a common complication of sys-
temic sclerosis (SSc) with poor progno-
sis. The aim of the current study was 
to detect potential myocardial inflam-
mation present in asymptomatic SSc 
patients by 18F-FDG-PET/CT and to 
investigate its relationship with early 
signs of myocardial dysfunction as de-
tected by 2D speckle tracking echocar-
diography (2DSTE).
Methods. Sixteen consecutive patients 
with SSc and 9 control patients with-
out clinical evidence of cardiac in-
volvement were enrolled in the study. 
On 18F-FDG-PET acquired images 
blood-pool normalised SUV ratio and 
heterogenity index (HI: standard devi-
ation of SUV divided with mean SUV) 
were calculated. Within 24 hours all 
SSc patients underwent 2DSTE strain 
analysis.
Results. Eight of 16 SSc patients were 
found to be visually PET-positive and 
showed significantly higher myocar-
dial 18F-FDG SUV ratio (1.78±0.74 
vs. 0.98±0.03; p<0.05) and heterogen-
ity index (0.13±0.02 vs. 0.05±0.02; 
p<0.001) as compared to the control 
group. FDG-PET/CT derived values 
did not differ significantly between 
visually PET-negative (8/16) and con-
trol patients (SUV ratio: 0.98±0.05 
vs. 0.98±0.03; HI:  0.05±0.01 vs. 
0.05±0.02). Global left ventricular 
longitudinal strain values did not dif-
fer significantly between PET-positive 
and negative patients (17.18±3.49% 
vs. 17.59±3.65%).
Conclusion. Myocardial inflammation, 
as a potential sign of early cardiac in-
volvement can be detected by 18-FDG-
PET/CT in a considerable percentage 
of systemic sclerosis patients present-
ing without cardiac symptoms.
Introduction 
Systemic sclerosis (SSc) is a rare, 
chronic, progressive systemic connec-
tive tissue disease characterised by mi-
crovascular dysfunction, immune-me-
diated inflammation and fibrosis with 
multi organ involvement. Cardiac in-
volvement is common for patients with 
SSc, both in diffuse (DcSSc) and lim-
ited cutaneous forms (LcSSC) of dis-
ease with an estimated clinical preva-
lence of 15-35% (1, 2). Cardiovascular 
disease in SSc may be direct (myocar-
ditis, heart failure, coronary artery dis-
ease, valvular and pericardial disease, 
conduction disturbances) and indirect 
(pulmonary artery hypertension (PAH) 
and renal crisis). When heart involve-
ment becomes clinically evident, it ap-
pears as a bad prognostic factor with a 
patient mortality rate of up to 70% at 
5 years (3). In the majority of patients 
(up to 80%), however cardiovascular 
disease is subclinical (4, 5) for variable 
duration. Therefore preclinical identi-
fication and monitoring of cardiac in-
volvement is pivotal for adequate early 
management of these patients.
Routine transthoracic echocardiogra-
phy (TTE) is the first line modality of 
choice in assessment of cardiac involve-
ment (6). Echocardiography deforma-
tion imaging, such as speckle-tracking 
echocardiography (STE) for measure-
ment of strain and strain rate, have been 
developed for a more accurate depiction 
of regional contractility and early de-
tection of myocardial dysfunction (7). 
Indeed several recent publications have 
verified the promising role of STE for 
early detection of myocardial dysfunc-
tion in SSc patients (8-11).
Although diffuse myocardial fibrosis re-
mains the pathologic hallmark of direct 
myocardial involvement (12), the pres-
ence of inflammation is often found in 
Detection of myocardial inflammation by 
18F-FDG-PET/CT in patients with systemic sclerosis 
without cardiac symptoms: a pilot study
Z. Besenyi1, G. Ágoston2, R. Hemelein3, A. Bakos1,  
F.T. Nagy4, A. Varga2, L. Kovács3, L. Pávics1
S-89Clinical and Experimental Rheumatology 2019
Cardiac FDG-PET/CT in systemic sclerosis / Z. Besenyi et al.
biopsies of SSc patients suggesting that 
cardiac inflammation may be more com-
mon than originally appreciated. Moreo-
ver, the fibrotic process may be second-
ary to chronic inflammation of the heart 
(13). 18F-fluorodeoxyglucose(FDG)-
positron emission tomography/com-
puted tomo-graphy (PET/CT) is a non-
invasive molecular imaging technique 
that is highly sensitive in quantitative 
evaluation of metabolically active pro-
cesses such as inflammation. 18-FDG-
PET/CT is generally gaining signifi-
cance in the detection and monitoring 
of cardiac inflammation and infection 
(14, 15). We hypothesised that 18F-
FDG-PET/CT may also be positive in 
asymptomatic SSc patients with poten-
tial subclinical myocarditis.
The aim of the current study was to de-
tect potential myocardial inflammation 
present in asymptomatic SSc patients 
by 18F-FDG-PET/CT. We also sought 
to investigate the relationship between 
pathological myocardial findings on 
18F-FDG-PET/CT and clinical indi-
ces of SSc disease and early signs of 
myocardial dysfunction as detected by 
2DSTE.
Patients and methods
Study population
Sixteen consecutive patients affected 
with SSc but without overt cardiovas-
cular involvement were enrolled in the 
current prospective study. Inclusion cri-
teria for the SSc group were: 1) age>18 
and <85 years; 2) a previous diagnosis 
of SSc according to the ACR EULAR 
guidelines for SSc classification (16). 
Exclusion criteria were: 1) inability to 
provide informed consent; 2) known 
history of coronary artery disease, 
electrocardiographic signs of myocar-
dial ischaemia, left ventricular ejection 
fraction <55%, regional wall motion 
abnormalities, left ventricular hypertro-
phy, significant valvular heart disease, 
pericardial effusion, severe pulmonary 
hypertension (pulmonary artery sys-
tolic pressure >40Hgmm). To avoid un-
necessary radiation exposure to healthy 
subjects, 9 persons (5 male, 4 female; 
age 46.55±18.05 years) who underwent 
FDG-PET/CT examination for various 
other diagnostic reasons were enrolled 
as controls. Control subjects did not 
have SSc, nor had evidence of active in-
flammatory disease or cardiac disease, 
complied otherwise with the general 
exclusion criteria, and underwent the 
same FDG-PET/CT image acquisition 
and analysis protocol as the study pa-
tients. All subjects gave informed con-
sent. The study was approved by the 
Local Ethical Committee for Clinical 
Research at the University of Szeged 
(ref. no.: 3647).
Laboratory and clinical assessment 
All SSc patients underwent compre-
hensive rheumatologic and cardio-
vascular evaluation including, but not 
limited to, the assessment of: disease 
duration, EUSTAR disease activity 
score (17), Framingham score (18), 
presence of gastrointestinal involve-
ment, pulmonary involvement, digital 
ulcers, prior immunosuppressive treat-
ment, cardiovascular risk factors and 
current medication. General laboratory 
workup including determination of dis-
ease specific autoantibodies and mark-
ers of inflammation were performed 
according to local practice guidelines. 
Creatinine-kinase (CK) as a marker of 
gross skeletal muscle/myocardial in-
jury was also ascertained (Table I).
18F-FDG-PET/CT image 
acquisition protocol 
To suppress physiological glucose up-
take in the myocardium patients were 
instructed to take low-carbohydrate, 
high-fat, high-protein diet for 24 hours 
followed by a minimum of 6 hours fast-
ing before PET/CT scan examinations 
according to previously published car-
diac FDG-PET/CT guidelines (19). A 
mean activity of 481.98±80.95 MBq 
(6,5 MBq/kg) FDG was administered 
intravenously. Blood glucose levels 
were checked (<8 mmol/L) beforehand. 
All scans were performed on an inte-
grated whole-body PET/CT system (GE 
Discovery ST 4, GE Healthcare, Amer-
sham, UK). Imaging of the cardiac re-
gion in 2D, non-gated mode was carried 
out 60 minutes after the administration 
of the radioisotope. PET scan data col-
lection was completed by low-dose CT 
(120 kV and 70 mAs) acquisition. After 
imaging of the cardiac region, a routine 
whole-body acquisition was performed 
in 3-dimensional mode, extending from 
the skull base to the upper third of the 
thighs. Images were reconstructed us-
ing a standard ordered subset expecta-
tion maximisation algorithm with CT 
for attenuation correction.
18F-FDG-PET/CT image 
analysis protocol
FDG-PET images were visually evalu-
ated for the presence of FDG uptake in 
the heart by consensus reading of two 
experienced PET/CT specialists. Based 
on uptake, FDG-PET images were clas-
sified into 4 patterns: “none,” “diffuse,” 
“focal,” and “focal on diffuse.” Quan-
titative evaluation of FDG uptake was 
performed by PMOD version 3.704 
software (PMOD Technologies Zu-
rich) on attenuation corrected 2D PET 
images. Reorientation of axial cardiac 
images was performed. Seventeen seg-
ments cardiac model was used accord-
ing to the scientific statement from 
the American Heart Association (20). 
Body weight standardised uptake value 
(SUV) in g/ml was calculated. Defini-
tion of left ventricular volume of inter-
est (VOI) was performed in a semi-au-
tomated fashion. Blood pool VOI was 
contoured in the left ventricular cavity. 
Mean global, segmental myocardial 
and blood pool SUV were calculated. 
To avoid misinterpretation due to dif-
fering patient metabolic characteristics, 
SUV values were divided by blood pool 
SUV to create normalised SUV ratios 
(21). To further specify pathophysi-
ological uptake a coefficient of vari-
ation as a metric of image heterogen-
ity was also determined. Average and 
standard deviation of SUV values were 
calculated from SUV values in the 17 
myocardial segments. The coefficient 
of variation (heterogenity index; HI) 
was calculated as the standard devia-
tion of SUV divided by the average of 
SUV (22). Widespread diffuse myocar-
dial FDG uptake exceeding liver uptake 
was considered as failed inhibition of 
physiological myocardial glucose up-
take and patients were excluded from 
further analysis (23).
Echocardiography
All patients with SSc underwent com-
prehensive echocardiography within 24 
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hours after PET/ CT scanning. Echo-
cardiographic examinations were per-
formed in all patients at rest using com-
mercially available ultrasound machine 
(Vivid S70, GE Medical Systems, Hort-
en, Norway). Left ventricular (LV) end-
diastolic and end-systolic diameters, 
interventricular septum diastolic (IVS), 
and posterior wall thickness (PW), left 
atrial (LA) volumes, maximum LA size 
measurements were performed. Early 
(E) and late (A) mitral inflow velocity, 
E/A ratio, and deceleration time were 
obtained. Systolic (S’), early diastolic 
(E’), and late diastolic (A’) velocities 
were also measured by tissue Doppler 
imaging (TDI). Pulmonary artery sys-
tolic pressure was estimated (24). All 
measurements were performed accord-
ing to the recommendations of the Eu-
ropean Association of Cardiovascular 
Imaging/American Society of Echo-
cardiography (25). 2D speckle tracking 
echocardiography (2DSTE) analyses 
were performed on standard echocar-
diographic grey-scale images. The 
loops were recorded with a frame rate 
between 60 and 80 frames per second. 
LV longitudinal strain was determined 
from the 3 apical (2-, 3-, and 4-cham-
ber) views. The 2D images were ana-
lysed using dedicated software package 
(EchoPac PC, version, GE Vingmed, 
Horton, Norway). During analysis, the 
endocardial border was manually traced 
at end systole, and the region of interest 
width was adjusted to include the entire 
myocardium. The software then auto-
matically tracks and accepts segments 
of good tracking quality and rejects 
poorly tracked segments while allow-
ing the observer to manually override 
its decisions on the basis of visual as-
sessments of tracking quality. Peak lon-
gitudinal strain values were determined 
in 17 segments by Bull’s eye method 
(Fig. 1). Based on a guideline published 
by the American Society of Echocardi-
ography and a meta-analysis of normal 
values, global longitudinal systolic peak 
strain (GLPS) values below 19.7% were 
considered pathological (25, 26).
Statistical analysis
Data are presented as mean ± standard 
deviation (SD) unless otherwise stat-
ed. Comparisons between FDG-PET/
Table I. Clinical characteristics of systemic sclerosis patients.
 All SSc patients DcSSc LcSSc
 n=16 n=8 n=8
Age (year) 59 ± (44-74) 62 ± (45-74) 57± (44-62)
Sex (male/female) 2 M/14 F 1M/7F 1 M/7 F
Disease duration (years) 5.56 ± 6.22 5.38 ± 6.56 5.75 ± 5.43
EUSTAR disease activity score 2.88 ± 1.77 3.75 ± 1.35 2 ± 1.38
Framingham score 2.81 ± 3 2.83 ± 2.25 2.79 ± 3.76
ANA positive (n) 11 5 6
ACA positive (n)* 6 0 6
anti-Scl70 positive (n)  4 4 0
DLCO (%) 49 ± 22 46 ± 27 52 ± 18
Pulmonary involvement (n) 10 6 4
Digital ulcers (n) 8 2 6
Gastrointestinal involvement (n) 13 7 6
Hypertension (n) 7 4 3
Hyperlipidaemia (n) 7 4 3
Diabetes (n) 3 1 2
Immunosuppressive treatment in the past (n) 8 6 2
Immunosuppressive treatment in the last 6 months (n) 4 4 0
Corticosteroid (up to 4 mg/day) treatment at the time 3 3 0 
   of PET/CT examination (n) 
Beta-blockers (n) 4 3 1
ACE-inhibitors/ARB (n) 5 4 1
Calcium Channel Inhibitors (n) 6 3 3
Statins (n) 5 3 2
Platelet aggregation inhibitor (n) 6 2 4
CK, U/l 99 ± 54.65 105.25 ± 63.96 86.5 ± 33.07
CRP, mg/L  19.40 ± 29.68 23.31 ± 39.08 15.50 ± 18.07
ESR, mm/h 28.10 ± 15.53 31.87 ± 15.44 24.32 ± 15.67
WBC, G/L 8.40 ± 2.10 8.85 ± 2.44 7.94 ± 1.75
ACA: anti-centromere antibody; ACE: angiotensin converting enzyme; ANA: antinuclear antibodies; 
anti-Scl70: anti-topoisomerase; ARB: angiotensin II receptor blocker; CK: creatinine-kinase; CRP: C-
reactive protein; DLCO: diffusing capacity of the lung for carbon monoxide; DcSSc: diffuse cutaneous 
systemic sclerosis; ESR: erythrocyte sedimentation rate; LcSSc: limited cutaneous systemic sclerosis; 
WBC: white blood cell count. *p<0.05.
Fig. 1. Longitudinal strain bull’s eye plot derived from two-dimensional speckle tracking in patient 
with systemic sclerosis. Decreased strain values in inferior and anterior segments.
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CT positive and negative, DcSSc and 
LcSSc patients were performed using 
Student’s t tests or by non-parametric 
Mann-Whitney U-test, as appropri-
ate. Comparisons between categorical 
variables were made with the Fisher’s 
exact test. All tests were two-sided and 
p-values <0.05 were considered statisti-
cally significant. Overall and segmen-
tal agreement between FDG-PET/CT 
and 2DSTE was assessed using Co-
hen’s kappa coefficients. Correlations 
between the two methods were tested 
by Pearson or Spearman’s correlation 
tests, as appropriate. All analyses were 
performed using JMPV.14 statistical 
software v.14 (SAS Institute Inc., Cary, 
NC, USA).
Results
Clinical characteristics of the SSc pa-
tient population are presented in Table 
I. Of the 16 patients 8 patients present-
ed with limited cutaneous and 8 with 
diffuse cutaneous form of systemic 
sclerosis. Clinically expected differ-
ences between the two subgroups were 
related to a more frequent need for im-
munosuppressive and low-dose corti-
costeroid therapy in the DcSSc group, 
and the differences between autoanti-
body positivity, although statistically 
significant difference was observed 
only with regard to anti-centromere 
antibody-positivity.
FDG-PET/CT
Dietary protocol to suppress normal 
glucose uptake was followed in all 16 
SSc patients and 9 control subjects. 
Low carbohydrate, high-fat, high-pro-
tein diet time was: 32.5±3.14 hours, 
while total fasting time direct before 
image acquisition was: 18.32±4.74 
hours. Blood glucose levels before ra-
diopharmaceutical administration were 
4.92±0.99 mmol/l. According to visual 
classification of cardiac FDG-PET im-
ages in SSc patients, 8/16 none, 0/16 
diffuse, 6/16 focal, 2/16 focal on dif-
fuse patterns were found. In all of the 
control subjects, the cardiac FDG-up-
take was near or equal to lower than 
blood pool activity meaning a “none” 
pattern (Fig. 2). In SSc patients, global 
myocardial SUV was 3.019±0.02 g/ml 
and blood pool SUV was 2.1±0.56 g/
ml. In control patients, the same values 
were 1.81±0.26 g/ml and 1.85±0.27 g/
ml (p<0.05). Normalisation accord-
ing to blood pool uptake SUV ratio in 
the patient population was 1.38±0.65 
and 0.98±0.03 in the control group 
(p<0.05). Heterogenity indices of SSc 
and control patients were 0.095±0.04 
and 0.05±0.02 (p<0.05). Of the 16 
SSc patients 8 visually “PET positive” 
(focal or focal on diffuse myocardial 
FDG uptake) patients showed signifi-
cantly increased normalised SUV ratio 
(1.78±0.74 versus 0.98±0.03, p<0.05) 
and a significantly higher heterogen-
ity index (0.13±0.02 vs. 0.05±0.02, 
p<0.001) as compared to the control 
group (Fig. 3). In contrast, in the 8 
visually “PET-negative” SSc patients, 
normalised SUV ratio and heterogenity 
index did not differ significantly from 
control subjects (normalised SUV ratio: 
0.98±0.05 vs. 0.98±0.03; HI: 0.05±0.01 
vs. 0.05±0.02). No significant differ-
Fig. 2. FDG-PET/CT examination of a control patient without known cardiovascular disease. FDG-PET/CT fused axial (A), coronal (B) and sagittal (C) 
slices. The images show successful dietary suppression of physiological myocardial glucose uptake with no focal or diffuse increased uptake. Global nor-
malised standard uptake ratio: 0.97, heterogenity index: 0.03. 
Fig. 3. FDG/PET-CT examination of a PET-positive systemic sclerosis patient presenting without clinical signs of primary cardiac involvement. 
A: Coronal FDG-PET image of chest. B: Axial FDG-PET/CT fused image of the heart. C:  Same level axial FDG-PET slice without CT fusion. PET images 
show increased focal FDG uptake (arrows) in the lateral wall in the presence of otherwise suppressed myocardial glucose uptake. Global normalised SUV 
ratio: 1.10, heterogenity index: 0.14. 
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ences were detected between the two 
groups in regards to clinical charac-
teristics and laboratory parameters 
(Table II). No correlations were found 
between FDG-PET/CT derived values 
and type of SSc, disease activity scores, 
disease duration and laboratory indices 
of inflammation or cardiac involvement 
and echocardiographic parameters.
Echocardiography
Due to poor acoustic window, com-
prehensive transthoracic echocardi-
ography, global and segmental strain 
measurements were unsuccessful in 1 
of 16 SSc patients. Echocardiography 
characteristics of the SSc patient popu-
lation are presented in Table III. There 
were no significant differences be-
tween DcSSc and LcSSc patients based 
on TTE parameters. There was also 
no statistically significant difference 
between PET positive and negative 
groups in regards to conventional TTE 
findings and, of special interest, global 
longitudinal peak strain (17.18±3.49 
vs. 17.59±3.65). No correlations were 
found between GLPS values and FDG-
PET/CT derived indices (global SUV, 
normalised global SUV and HI).
Spatial agreement
Spatial agreement between FDG-PET/
CT and 2DSTE derived segmental lon-
gitudinal strain was assessed according 
to the 17- segment model in a total of 
234 left ventricular segments. Over-
all, 96/234 segments with increased 
FDG-uptake were found. According to 
2DSTE analysis 48/234 segments had 
pathological low segmental longitudi-
nal strain value. Overall and PET posi-
tive patient spatial agreement between 
the two methods was poor (κ=0.04 and 
κ=0.021). To avoid possible orienta-
tion bias for further analysis, the left 
ventricular bull’s eye was divided into 
four anatomical regions: apex (13-17 
segments), septum (2-3, 8-9 segments), 
anterior and anterolateral wall (1,6,7,12 
segments) and inferior and inferolat-
eral wall (4,5,10,11 segments). Patho-
logical FDG-PET/CT (20/56) and STE 
derived segmental longitudinal strain 
(21/56) regions were determined. 
Overall and in patients with pathologi-
cal PET findings, spatial agreement be-
tween the two methods remained to be 
poor (κ=0.12 and κ=0.15). 
Discussion
To the best of our knowledge, this is 
the first study to investigate early stage 
myocardial involvement in SSc patients 
with FDG-PET/CT. We prospectively 
evaluated the myocardial glucose meta-
bolic activity in SSc patients without 
clinical signs of primary cardiac in-
volvement and compared it to normal 
control subjects. Major finding of our 
study is that pathological myocardial 
FDG uptake as a sign of inflammation 
can be found in a significant number of 
SSc patients with otherwise no clinical 
evidence of cardiovascular disease.
The pathological hallmark of cardiovas-
cular involvement in SSc is patchy myo-
cardial fibrosis reported in up to 80% of 
cases in autopsy studies (12). Pathways 
leading to this final stage of disease are 
multifactorial. Recurrent episodes of 
ischaemia-reperfusion injury provoked 
by microvascular dysfunction (27) and 
vasospasm of small coronary arterioles, 
play a significant role in the develop-
ment of patchy “contraction band ne-
crosis” leading to fibrosis. The inflam-
matory and autoimmune nature of SSc 
and association with skeletal myositis 
suggests that myocardial inflammation 
my also play a crucial role in the devel-
opment heart disease in SSc. Historical-
ly, overt myocarditis had only been re-
ported in isolated cases of SSc patients 
with acute and severe cardiac symptoms 
Table II. Clinical characteristics of PET positive and PET negative systemic sclerosis 
patients.
 PET positive  PET negative
 n=8 n=8
Age (year) 58 (44-74) 61 (55-67)
Sex (Male/Female) 0 M/ 8 F 2 M/ 6 F
Disease duration (years) 7.65 ± 6.96 3.5 ± 4.95
EUSTAR disease activity score 2.75 ± 1.66 3 ± 1.96
Framingham score 2.13 ± 3.53  3.47 ± 3.53 
DcSSc (n) 4 4
LcSSc (n) 4 4
ANA positive (n) 5 6
ACA positive (n) 4 2
anti-Scl70 positive (n)  0 4
DLCO (%)  53 ± 27 46 ± 16
Pulmonary involvement (n) 5  5
Digital ulcers (n) 4 4
Gastrointestinal involvement (n) 6 7
Hypertension (n) 3 4
Hyperlipidaemia (n) 4 3
Diabetes (n) 0 3
Immunosuppressive treatment in the past (n) 4 4
Immunosuppressive treatment in the last 6 months (n) 2 2
Corticosteroid treatment (up to 4 mg/day) at the time  0 3
   PET/CT examination (n) 
Beta-blockers (n) 0 4
ACE-inhibitors/ARB (n) 2 3
Calcium Channel Inhibitors (n) 4 2
Statins (n) 2 3
Platelet aggregation inhibitors (n) 2 4
CK U/l 96.6 ± 65.09 100.71 ± 51.41 
CRP, mg/L   22.43 ± 38.82  16.35 ± 18.98 
ESR, mm/h 31.12 ± 18.60  25.8 ± 13.03 
WBC, G/L 8.6 ± 1.47  8.2 ± 2.69 
EF (%) 69.87 ± 5.59 65.12 ± 7.35
GLPS (%) 17.18 ± 3.49 17.59 ± 3.65
There were no statistically significant differences between PET positive and PET negative systemic 
sclerosis patients.
ACA: anti-centromere antibody; ACE: angiotensin converting enzyme; ANA: antinuclear antibodies; 
anti-Scl70: anti-topoisomerase; ARB: angiotensin II receptor blocker; CK: creatinine-kinase; CRP: C-
reactive protein; DLCO: diffusing capacity of the lung for carbon monoxide; DcSSc: diffuse cutaneous 
systemic sclerosis; EF: ejection fraction; ESR: erythrocyte sedimentation rate; GLPS: global longitu-
dinal peak systolic strain; LcSSc: limited cutaneous systemic sclerosis; WBC: white blood cell count.
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(28-30). More recently however, in an 
endomyocardial biopsy study of 25 SSc 
patients presenting with clinical signs of 
cardiac involvement at least low grade 
inflammation was diagnosed in almost 
all of the patients and high grade myo-
cardial inflammation was present in 20 
% of the cases (31). This was confirmed 
by Pieroni et al. (32) who in an even 
larger cohort of SSc patients with newly 
developed symptoms of heart failure 
and cardiac involvement proved myo-
carditis to be a common finding. Due to 
the poor prognosis of clinically manifest 
cardiovascular disease in SSc, early de-
tection of myocardial involvement has 
become a crucial aspect of patient man-
agement. Screening imaging modalities 
to identify early myocardial involve-
ment have concentrated on the detection 
of fibrosis and/or consequential myocar-
dial dysfunction (33, 34). More recently, 
advances in magnetic resonance imag-
ing (MRI) technology have allowed an 
early detection of surrogate parameters 
of inflammation, indicative of myocar-
dial inflammatory processes. Indeed 
MRI has proven to be a useful tool to 
detect myocardial inflammation in sev-
eral forms of rheumatic disorders: rheu-
matoid arthritis (35), systemic lupus 
erythematosus (SLE) (36), ankylosing 
spondylitis (37), ANCA-associated vas-
culitis (38). However, MRI has its limi-
tations, which are particularly apparent 
in chronic myocarditis with diagnostic 
accuracy as low as 50% (39).
Increased glucose metabolism due to 
high glycolytic activity of inflammatory 
cells (monocyte, macrophage, lympho-
cyte) is considered a hallmark of in-
flammation. Thus PET using 18F-FDG 
is the standard reference for molecular 
imaging of myocardial inflammation 
(40). At the present time FDG-PET/CT 
is already clinically established in the 
diagnosis and follow up of cardiac sar-
coidosis (41). It is also gaining accept-
ance in the detection and monitoring 
myocarditis in general (42). 18F-FDG 
PET has shown showed excellent agree-
ment with endomyocardial biopsy for 
detecting active inflammatory foci in 
subjects with clinically suspected active 
acute myocarditis (43). 18F-FDG PET 
may also provide useful information in 
addition to cardiac magnetic resonance 
(CMR) to distinguish between acute and 
chronic myocardial inflammation (44, 
45). Potential feasibility of PET scan 
with 18F-FDG to detect and monitor 
active cardiac involvement and treat-
ment efficacy in patients with systemic 
sclerosis has been reported in one case 
(46). In the current study we report the 
presence of myocardial inflammation 
detected by FDG-PET/CT in SSc pa-
tients without cardiac symptoms. These 
findings are in agreement with previous 
reports based on CMR imaging (47, 48). 
Our results are also similar to those of 
Perel-Winkler et al. who detected myo-
cardial inflammation by 18F-FDG-PET-
CT not only in symptomatic but also in 
asymptomatic SLE patients (49). PET 
positive patients were identified by in-
creased FDG uptake paired with het-
erogeneous distribution according to the 
pathophisology of disease presentation 
by “patchy” immune-inflammatory foci 
(50). PET positive patients exhibited 
significantly higher FDG uptake and 
heterogeneity index as compared to both 
FDG negative and control patients. Inci-
dence of subclinical myocardial inflam-
mation of 50% was comparable to one 
CMR based investigation (53%) (47), 
and significantly higher than in another 
10% (48). However, authors in the later 
study acknowledged that the low inci-
dence reported by them was probably 
due to the lack of T1, T2 mapping and 
extracellular volume assessment (48). 
Although the relatively low number of 
patients prevented conclusive compari-
sons between PET-positive and -nega-
tive SSc patients, some differences are 
apparent. It is somewhat unexpected 
that all the anti-Scl70-positive patients 
had negative PET-CT results, although 
this antibody is known to be associated 
with a higher risk of cardiopulmonary 
parenchymal organ involvement. It co-
incides with the finding that all 3 pa-
tients who were taking moderate dose 
of methylprednisolone (up to 4 mg) 
clustered in the PET-negative subgroup. 
These 3 patients were also anti-Scl70 
positive, and even this low dose of cor-
ticosteroid therapy may have had an 
impact on the myocardial inflammatory 
process. Underlining the subclinical 
nature of disease presentation, no sig-
nificant differences between laboratory 
indices of inflammation or myocardial 
necrosis were identified between PET 
positive and negative patients similarly 
to several other studies (10, 47, 48). 
There was also no significant difference 
between PET positive and negative pa-
tients in regards to disease activity, dis-
ease duration or disease type (DcSSc vs. 
LcSSc). We note that the primary aim 
of our work was to evaluate whether it 
is feasible to detect early myocardium 
involvement in SSc by FDG-PET/CT. 
The study population was thus select-
ed with a relatively strict exclusion of 
cardiovascular factors unrelated to SSc 
but otherwise represented an unselected 
and heterogeneous group with regard 
to SSc clinical manifestations. Valida-
tion of clinical correlations is out of the 
scope of this work and requires further 
studies. 
Table III. Echocardiographic parameters of systemic sclerosis patients.
 All SSc patients DcSSc LcSSc
LVEF (%) 67.5 ± 6.77 66.5 ± 7.96 68.5 ± 5.70
LV EDD (mm) 46.06 ± 3.02 45.63 ± 3.15 46.5 ± 3.02
LV IVS (mm) 9.62 ± 1.08 10.13 ± 0.83 9.12 ± 1.12
LV PW (mm) 9.56 ± 1.31 10.00 ± 1.41 9.12 ± 1.12
LA V (ml) 59.88 ± 20.25 56.54 ± 21.78 63.22 ± 19.45
E/A 0.91 ± 0.39 0.89 ± 0.41 0.92 ± 0.40
E/E’ 10.57 ± 3.97 12.54 ± 4.93 8.89 ± 2.03
TAPSE (mm) 22.86 ± 4.71 22.00 ± 5.03 23.62 ± 4.62
PASP (Hgmm) 28.3 ± 6.40 34.67 ± 3.51 25.57 ± 5.38
GLPS (%)  17.37 ± 3.44 15.61 ± 3.97 18.91 ± 2.10
There were no statistically significant differences between DcSSc and LcSSc patient groups.
A: late mitral inflow velocity; DcSSc: diffuse cutaneous systemic sclerosis; E: early mitral inflow 
velocity; E’: early diastolic velocity; EDD: end diastolic diameter; EF: ejection fraction; GLPS: global 
longitudinal peak systolic strain; LA V: left atrial volume; LcSSc: limited cutaneous systemic sclero-
sis, LV: left ventricular; IVS: intraventricular septum; PASP: pulmonary artery systolic pressure; PW: 
posterior wall; TAPSE: tricuspid annular plane systolic excursion.
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Echocardiography is an essential, first 
line, noninvasive method to detect car-
diac involvement in patients with SSc. 
Common pathological findings in overt 
disease may include wall motion dis-
turbances, reduced ejection fraction, 
pericardial effusion and PAH. Recently 
echocardiographic deformation imag-
ing modalities such as STE strain anal-
ysis have been developed to provide 
more accurate depiction of regional 
contractility and dysfunction otherwise 
not seen with routine parameters. Sev-
eral STE studies have described sub-
clinical left ventricle (8), right ventricle 
(9) and left atrial dysfunction (10) in 
asymptomatic SSc patients as markers 
of early myocardial involvement. In 
the current study, we report decreased 
left ventricle GLPS values indica-
tive of subtle myocardial dysfunction 
in asymptomatic SSc patients. These 
results are in accordance with previ-
ously published findings (8, 51). We 
found no significant differences in left 
ventricular GLPS values between PET 
positive and negative groups. Accord-
ingly, no significant correlations were 
found between left ventricular GLPS 
values and the measures of pathological 
glucose uptake (normalised SUV ratio, 
HI). We also investigated spatial agree-
ment between the two methods on seg-
mental and regional basis as well. Our 
study demonstrated poor agreement of 
FDG-PET/CT and left ventricular strain 
in regards to spatial distribution of im-
aging findings. These differing results 
between FDG-PET/CT and 2D speckle 
tracking echocardiography strain analy-
sis maybe explained by the two differ-
ent phases of disease evolution is SSc. 
In myocardial biopsy studies inflam-
matory infiltrates were recognisable as 
a form of early phase immune modu-
lated interstitial/perivascular inflamma-
tion which may ultimately lead to the 
second phase of disease, replacement 
fibrosis (13, 30). The results capture the 
dual nature of the disease: pathologi-
cal glucose uptake representing early 
immune mediated inflammation and 
lower strain values representing subtle 
mechanical changes caused by fibrosis.
Distinct differences between the two 
imaging modalities should also be 
noted in regards to clinical implemen-
tation. Echocardiography is a validated, 
readily available noninvasive screening 
tool to detect and follow myocardial 
involvement in patients with systemic 
sclerosis. On the other hand, routine 
clinical use of FDG-PET-CT is not rec-
ommended at this time and before pos-
sible clinical implementation further 
investigations are warranted to evaluate 
specificity, sensitivity and overall clini-
cal impact (prognostic value, therapeu-
tic relevance) of the method in asymp-
tomatic SSC patients. Until then we 
suggest that asymptomatic FDG-posi-
tive patients should be followed more 
closely with currently validated cardiac 
techniques (i.e. CMR).
Limitations of the study
Some limitations of the study should be 
noted. First: the sample size was small 
due to the pilot nature of the study and 
the rare incidence of SSc. Addition-
ally, we excluded patients with overt 
cardiac symptoms, already diagnosed 
cardiovascular disease further narrow-
ing the patient population pool. Second: 
the study lacks a true comparator for 
myocardial inflammation as detected by 
FDG-PET/CT. Standard of reference or 
lack thereof is a common problem when 
evaluating imaging modalities for myo-
carditis. Endomyocardial biopsy (EMB) 
is still considered the gold standard for 
diagnosing myocarditis. However, it is 
not frequently performed due to risk, 
cost, variable specificity, and lack of 
experience in some facilities (42). EMB 
in the current, asymptomatic patient 
population was not considered because 
of its invasive nature and potential risks. 
In the recent decades CMR has gained 
wide acceptance both as a research tool 
and as a clinical diagnostic method in 
myocarditis. Although CMR is the most 
validated imaging method of myocar-
ditis it still is not considered to be gold 
standard. In one study for example it 
was non-decisive or falsely negative in 
half of patients with biopsy-proven my-
ocarditis (52). Nonetheless CMR should 
be considered as first choice compara-
tor in future studies. Furthermore, pos-
sible simultaneous assessment of car-
diac inflammation and fibrosis using an 
integrated FDG-PET/MR examination 
would be particularly well suited for 
comparative studies. Initial experiences 
with this hybrid method to detect myo-
cardial involvement in cardiac sarcoido-
sis (53) and in suspected myocarditis 
(23) have been promising. Third: patho-
logical 18-FDG detected by FDG-PET/
CT is highly sensitive, but nonspecific 
method for visualisation of inflamma-
tion. Due to lack of standardisation in 
regards to patient preparation, reporting 
of images and – as mentioned above – a 
true comparator, false positive diagnosis 
is possible. Two patients in the current 
study exhibiting “focal on moderately 
elevated” diffuse uptake could poten-
tially also be interpreted as false posi-
tive due to unsuccessful physiologic 
glucose uptake suppression. Fourth: 
concomitant corticosteroid therapy at 
the time of FDG-PET/CT examination 
therapy, even in low doses, may mask 
potential underlying low-grade myocar-
dial inflammation, potentially leading to 
false negative results. Fifth: the study 
lacks a matched, healthy control popula-
tion for 2DSTE imaging. Limitations of 
2DSTE analysis include intervendor and 
patient-specific clinical factor variabil-
ity. Strain values are influenced by age, 
concomitant cardiovascular risk factors, 
haemodynamic values, and medication. 
Thus, the definition of normal strain 
values remains problematic (54). None-
theless a guide on normal values by the 
American Society of Echocardiography 
and previously published meta-analysis 
of normal ranges in healthy subjects al-
low for a meaningful interpretation of 
our results (25, 26).
Conclusion
Myocardial inflammation, as a potential 
sign of early cardiac involvement may 
be detected by 18-FDG-PET/CT in a 
considerable percentage of systemic 
sclerosis patients presenting without 
cardiac symptoms. We hypothesise that 
this imaging method has the potential to 
be used as a new diagnostic tool for the 
evaluation of SSc patients. However, it 
is evident that before clinical implemen-
tation further clinical investigations are 
warranted in larger patient groups to de-
termine the prognostic impact of these 
findings and to identify specific patient 
risk groups in whom this examination 
may be of direct therapeutic relevance.
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